B+
Bull case
25%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
SGHT
Sight SciencesBNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
55%
Probability
Target price
$8.60
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
20%
Probability
Target price
$5.30
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+72.2
Score
AI commentary
The post-earnings tone is positive based on reported growth, raised revenue guidance, lower adjusted operating-expense guidance, reimbursement expansion, and product clearance. However, coverage is low, social and options evidence are unavailable, and post-print analyst revisions or target changes were not confirmed. The $7.09 anchor suggests the initial reaction was constructive, but this remains a monitoring-style view.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-05eventQ2 revenue acceleration and raised FY26 outlookMedium impact
Q2 revenue was $23.4 million, up 20% year over year; Interventional Glaucoma grew 8% and Interventional Dry Eye grew 704%. FY26 revenue guidance increased to $88-$92 million from $83-$89 million, while adjusted operating-expense guidance declined to $92-$94 million from $93-$96 million. [#SEC-8K-2026-08-05] [#8-K-2026-08-05]
2026-11-06catalystCash-burn and margin execution checkHigh impact
Q2 net loss was $4.4 million and cash usage was $5.2 million, although normalized cash usage was $1.4 million after one-time items. Excluding tariff refunds, gross margin was 86%; sustained expense discipline remains important. [#SEC-8K-2026-08-05]
2027-08-08catalystReimbursement expansion supporting procedure adoptionHigh impact
IDE reimbursed-access lives increased from approximately 10.4 million to 14.5 million, while Aetna added approximately 25 million commercial covered lives for eligible glaucoma procedures. Eligibility may take time to convert into utilization. [#SEC-8K-2026-08-05]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology